Trial
NCT01258933
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
GlaxoSmithKline
Condition
Leukemia
Intervention
Ofatumumab
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-01